Ranbaxy and Teva announce generic Lipitor agreement

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited ("Ranbaxy"), a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva.

Atorvastatin Calcium Tablets are the generic version of Pfizer's Lipitor® Tablets. Annual sales of Lipitor® were approximately $7.8 billion in the United States as of September 2011, based on IMS sales data.


Teva Pharmaceutical Industries Ltd.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Alzheimer’s study on mice reveals important mechanism behind neural hyperactivity